IRVINE, Calif., June 19, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., (“MSL” or “the Company”), a leading developer of precision diagnostic…
PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical…